Loading HSIC detail
Loading ticker data...
Loading HSIC detail
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide.
It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services.
Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Chart data unavailable
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, today announced its plan to reduce the size of its Board of Directors following its 2026 Annual Meeting of Stockholders on May 21, 2026. Stanley M. Bergman is to retire from the Board after 44 years as a director of Henry Schein. In recognition of Mr. Bergman's leadership and the significant contributions he has made to the Co.
Ari Sass of the M.D. Sass Concentrated Value ETF is hunting for reasonably priced growth stocks like Henry Schein.
Shares of Henry Schein, Inc. (NASDAQ: HSIC - Get Free Report) have received a consensus recommendation of "Hold" from the thirteen brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?
HSIC's growth from its Henry Schein One venture and partnerships is promising, but macro pressures and stiff competition raise concerns for investors.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, has been recognized as one of the 2026 World's Most Ethical Companies® by Ethisphere, a global leader in defining and advancing the standards of ethical business practices. “To be honored for our ethical practices reflects the values that have guided Henry Schein for decades,” said Fred M. Lowery, Chief Executive Officer of He.
Cooper Companies (NASDAQ: COO - Get Free Report) and Henry Schein (NASDAQ: HSIC - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership. Earnings and Valuation This table compares Cooper Companies
Henry Schein, Inc. is rated a 'Buy' as signs of improving growth and undervaluation emerge despite recent stagnation. HSIC's recent results show solid revenue and EPS growth, but operating margins and ROIC remain pressured, challenging its economic moat. Management guides for 3–5% sales growth and 5–8% non-GAAP EPS growth in 2026, supported by strategic focus on high-margin businesses and digital transformation.
Henry Schein, Inc. (HSIC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
AMERICAN FORK, Utah--(BUSINESS WIRE)--Henry Schein One, the market leader in dental practice management systems, today unveiled the next era of Dentrix Ascend—introducing three new packages built on a fully integrated, agentic platform architecture designed to help practices and Dental Service Organizations (DSOs) increase revenue and accelerate growth. The new offering strengthens Dentrix Ascend's position as the platform of choice for modern dental organizations while advancing Henry Schein O.
Dimensional Fund Advisors LP increased its holdings in shares of Henry Schein, Inc. (NASDAQ: HSIC) by 6.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,596,168 shares of the company's stock after acquiring an additional 159,087 shares during the period. Dimensional
Henry Schein, Inc. (HSIC) Presents at Leerink Global Healthcare Conference 2026 Transcript
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
